Other research analysts have also recently issued research reports about the stock. Brean Capital reiterated a buy rating on shares of Horizon Pharma in a research report on Tuesday, August 2nd. Guggenheim reissued a buy rating and set a $30.00 target price on shares of Horizon Pharma in a research note on Monday, August 1st. Vetr raised shares of Horizon Pharma from a hold rating to a buy rating and set a $19.82 target price for the company in a research note on Tuesday, June 7th. Goldman Sachs Group Inc. assumed coverage on shares of Horizon Pharma in a research note on Monday, June 6th. They set a buy rating and a $24.00 target price for the company. Finally, Stifel Nicolaus reissued a buy rating and set a $45.00 target price on shares of Horizon Pharma in a research note on Wednesday, July 6th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $30.00.
Shares of Horizon Pharma (NASDAQ:HZNP) opened at 18.77 on Thursday. Horizon Pharma has a 12 month low of $12.86 and a 12 month high of $23.70. The firm’s 50-day moving average is $19.59 and its 200 day moving average is $17.72. The stock’s market cap is $3.02 billion.
Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.12. Horizon Pharma had a negative net margin of 0.34% and a positive return on equity of 23.46%. The business had revenue of $257.40 million for the quarter, compared to analysts’ expectations of $235.43 million. During the same quarter in the previous year, the business posted $0.39 earnings per share. The business’s revenue was up 48.9% compared to the same quarter last year. On average, equities analysts predict that Horizon Pharma will post $2.15 EPS for the current year.
In other Horizon Pharma news, EVP Jeffrey W. Sherman sold 2,900 shares of the stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $20.00, for a total transaction of $58,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 2.10% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in HZNP. BlackRock Fund Advisors raised its stake in Horizon Pharma by 127.3% in the second quarter. BlackRock Fund Advisors now owns 6,678,136 shares of the biopharmaceutical company’s stock valued at $109,989,000 after buying an additional 3,740,449 shares during the last quarter. State Street Corp increased its position in Horizon Pharma by 149.1% in the second quarter. State Street Corp now owns 4,201,164 shares of the biopharmaceutical company’s stock valued at $69,194,000 after buying an additional 2,514,430 shares during the period. Deerfield Management Co. increased its position in Horizon Pharma by 17.6% in the first quarter. Deerfield Management Co. now owns 13,740,261 shares of the biopharmaceutical company’s stock valued at $227,676,000 after buying an additional 2,055,460 shares during the period. Fiera Capital Corp bought a new position in Horizon Pharma during the second quarter valued at about $28,892,000. Finally, BlackRock Institutional Trust Company N.A. increased its position in Horizon Pharma by 57.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 3,673,204 shares of the biopharmaceutical company’s stock valued at $60,498,000 after buying an additional 1,335,251 shares during the period. 85.25% of the stock is owned by institutional investors and hedge funds.
About Horizon Pharma
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
Receive News & Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.